Mark Velleca

Title: Mark Velleca: Innovator in Pharmaceutical Chemistry

Introduction

Mark Velleca is a notable inventor based in New Haven, CT (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit Bruton's tyrosine kinase. His work has implications for treating various diseases, including cancer and autoimmune disorders.

Latest Patents

Mark Velleca holds a patent for "Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds." This patent describes compounds of Formula I-a and their pharmaceutically acceptable forms. The patent outlines pharmaceutical compositions that contain these compounds, along with methods for treating patients suffering from diseases responsive to tyrosine kinase inhibition. The diseases targeted include cancer, autoimmune diseases, and acute inflammatory reactions. The methods involve administering effective amounts of the compounds to alleviate symptoms or slow disease progression.

Career Highlights

Mark Velleca is currently associated with Cgi Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His work focuses on developing new therapeutic strategies that leverage his patented compounds. His contributions have been instrumental in advancing the understanding of tyrosine kinase activity and its role in various diseases.

Collaborations

Mark has collaborated with notable colleagues, including Robert W DeSimone and Kevin S Currie. These collaborations have fostered a productive environment for research and development, leading to advancements in pharmaceutical applications.

Conclusion

Mark Velleca's innovative work in pharmaceutical chemistry, particularly in the development of compounds targeting Bruton's tyrosine kinase, showcases his commitment to improving treatment options for serious diseases. His contributions continue to have a significant impact on the field.